UK-based Amphista Therapeutics has unveiled new data demonstrating the potential of its protein degraders in animal models, a step toward bringing the tech to the clinic. The findings showed the therapies reduced tumor size and boosted survival, the biotech said in a Jan. 24 release. Source: Fierce Biotech 24/1/2024